Genefab — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

GeneFab is a private, revenue-generating contract development and manufacturing organization (CDMO) with a specialized biofoundry focus on cell and gene therapies. The company leverages deep synthetic biology expertise and a 'Process & Analytical Development mindset' to help client innovators overcome manufacturing bottlenecks and accelerate their programs. With facilities in Alameda and South San Francisco, California, and a leadership team boasting extensive industry experience, GeneFab positions itself as a strategic partner for biotechs navigating the complex path from genetic design to clinical and commercial-scale production. Its business model is entirely service-based, supporting client programs rather than developing an internal therapeutic pipeline.

AntibodiesProteomicsDiagnostics

Technology Platform

Integrated CRDMO biofoundry combining synthetic biology/gene design, process & analytical development (PAD), and GMP manufacturing platforms for autologous and allogeneic cell and gene therapies.

Opportunities

The rapid growth of the cell and gene therapy sector, coupled with the pervasive manufacturing bottleneck faced by innovator biotechs, creates a large and expanding market for specialized CDMOs.

GeneFab's deep technical expertise and focus on client partnership position it to capture significant market share as the demand for outsourced development and manufacturing services increases.

Risk Factors

Key risks include dependence on a limited client base and the success of their therapeutic programs, intense competition from larger and niche CDMOs, operational risks associated with complex cell therapy manufacturing, and vulnerability to downturns in biotech funding which would reduce client R&D spending.

Competitive Landscape

GeneFab competes in the crowded and competitive cell and gene therapy CDMO space. It faces competition from large, diversified global CDMOs (e.g., Lonza, Catalent, Thermo Fisher), as well as other focused pure-play CGT CDMOs (e.g., Oxford Biomedica, Brammer Bio, Andelyn Biosciences). Its differentiation is its strong emphasis on synthetic biology, a 'partner' mentality, and deep team experience from innovator companies.

More companies in Cell & Gene Therapy →More companies in United States →